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Introduction 
Gas-filled microbubbles have the potential to become a unique MR contrast agent due to their magnetic susceptibility effect, biocompatibility and localized 
manipulation via ultrasound cavitation. In this study, two types of microbubbles, custom-made albumin-coated microbubble (A-MB) and a commercially available lipid-
based clinical ultrasound microbubble contrast agent (SonoVue®), were examined as intravascular MR brain contrast agents using dynamic susceptibility MRI in 
Sprague-Dawley (SD) rats at 7 Tesla. 
Methods 
Microbubble Preparation and Animal Procedures: SonoVue® microbubbles (Bracco) consist 
of sulphur hexafluoride gas stabilized in aqueous dispersion by phospholipid monolayer. Air-
filled A-MBs were produced by sonication as previously described [1]. Briefly, 5% bovine 
serum albumin (USB) solution was preheated to about 70 ºC and sonicated using 20 kHz 
ultrasound.  Five normal SD rats (~250-350 g) were used. Each rat was anesthetized with IP 
injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). Femoral vein catheterization was 
performed with a 1-m long tube (Braintree) connected to a 27-gauge needle. The dead space in 
the catheter was about 0.2 mL. During imaging, animals were anesthetized with isoflurane/air 
using 1.0-1.5% via a nose cone with respiratory monitoring. 
Microbubble Administration: Microbubbles were first warmed slowly to room temperature. A-
MB suspension was resuspended by inversion and rotation for 2 min until a homogenous 
milky-white suspension formed. For SonoVue®, 1.2 mL sodium chloride 0.9% w/v solution 
was used for dispersion of powder in the vial. Resuspension was performed by vortexing for 
~20 s until a homogenous suspension formed. For each imaging session, 0.2 mL of 
microbubble suspension (of ~4% volume fraction for A-MB and ~3.5% volume fraction for 
SonoVue®) was slowly injected (over ~10 s) into femoral vein at a rate of 1.2 mL/min to 
avoid possible microbubble destruction due to high pressure and shear stress. 
MRI: All MRI experiments were performed on a 7 T Bruker MRI scanner using a 38-mm 
quadrature RF resonator. Anatomical images were acquired with 2D FLASH sequence with 
resolution = 0.20 × 0.20 × 2.0 mm3. Dynamic susceptibility weighted MRI was performed 
with single-shot GE-EPI sequence using TR = 1000 ms, TE = 30 ms, FA = 90º, FOV = 29 mm 
× 29 mm, slice thickness = 0.7 mm, acquisition matrix = 96 × 96, BW = 221 kHz and NEX = 
1. Microbubble suspension was injected about 5 min after the start of dynamic imaging. A 
minimum lapse of 10 min was used to ensure sufficient clearance of the microbubbles before 
the next injection. The susceptibility effect of microbubbles was compared with that of a well-
established intravascular contrast agent, monocrystalline iron oxide nanoparticles (MION; 
MGH), in brain by single dose of 0.6 mg Fe/kg injection using identical injection protocol and 
imaging sequence. 
Image Analysis: GE-EPI images were first co-registered using AIR5.2.5 [2]. ΔR2* maps were 
computed on a pixel-by-pixel basis as ΔR2* = ln (Spre/Savg-post)/TE, where Spre is the average 
intensity in 100 preinjection images and Savg-post is the average intensity in 40 postinjection 
images with maximum susceptibility contrast for microbubbles (or 100 postinjection images at 
steady-state contrast for MION). To quantify the ΔR2* values, ROIs were manually drawn in 
cortex (Ctx), cauduate putamen (CPu) and blood vessel (BV) regions based on the high 
resolution FLASH images. Assuming that ΔR2* is proportional to microbubble concentration 
C(t) at time t, C(t) can be estimated as C(t) = k ln {Spre/S(t)}/TE + CB, where S(t) is the image 
intensity at time t, k a proportionality constant, and CB a constant residue to account for any 
postinjection baseline [3]. Given the relatively long injection time and the limited lifetime of 
microbubbles in vivo, C(t) were approximately modeled with a gamma-variate function by 
curve fitting [4]. Full width at half maximum (FWHM) and time-to-peak were then measured 
from the fitted C(t) time courses. 
Results and Discussion 
Fig. 1 and 2 illustrate the rat brain images typically observed during A-MB injection (0.2 mL 
of ~4% volume fraction) and SonoVue® injection (0.2 mL of ~3.5% volume fraction) 
respectively. Note that the microbubbles induced ∆R2* maps were observed to be similar to 
those caused by intravascular MION. Table 1 shows the in vivo measurements of the ∆R2*, 
FWHM and time-to-peak of A-MB and SonoVue® as well as the ∆R2* and time-to-peak of 
MION in cortex area among all rats studied. With identical injection protocol, time-to-peak 
was found to be shorter for MION. This is largely expected as microbubbles, with size 
comparable to that of red blood cells, flow slower than blood plasma while MION 
nanoparticles flow together with plasma. ∆R2* was 2.49 ± 1.00 s-1, 2.41 ± 1.18 s-1 and 1.98 ± 
0.36 s-1 for A-MB, SonoVue® and MION, respectively. This indicates that the in vivo 
susceptibility effects of A-MB and SonoVue® at the dosage used are comparable to that of 0.6 
mg Fe/kg MION in brain tissue at 7 T. 
Conclusion 
We demonstrated, for the first time, the feasibility of gas-filled microbubbles as an 
intravascular susceptibility contrast agent for brain MRI at 7 T. Considerable susceptibility 
induced changes were observed and characterized in rat brains using custom-made albumin-
coated microbubbles and a commercially available clinical ultrasound microbubble contrast 
agent. The results indicate that microbubbles can serve as a unique intravascular MR contrast 
agent at high field. As microbubble fabrication technology is advancing, substantially 
increased in vivo lifetime by using surfactant molecules [5] and molecular targeting capability 
by means of ligand incorporation [6] have been demonstrated. All together, these technologies 
may enable microbubble MRI to provide effective real-time imaging guidance in various 
microbubble-based drug delivery and therapeutic applications. 
 
 
Fig. 1. Typical images from a rat brain during A-MB injection (0.2 mL 
of ~4% volume fraction over ~10s): (a) anatomical image; (b) 
preinjection GE-EPI T2*-weighted image; (c) postinjection GE-EPI T2*-
weighted image with the maximum susceptibility contrast; (d) T2*-
weighted signal time courses in different ROIs during A-MB injection; 
(e) ∆R2* map computed from A-MB data; and (f) ∆R2* map obtained
using intravascular contrast agent MION at 0.6 mg Fe/kg. Three ROIs 
used for time course measurements are shown in (b) and gamma-variate 
fitted data shown in sold lines. 
 
Fig. 2. Corresponding images from a rat brain during SonoVue® 
injection (0.2 mL of ~3.5% volume fraction over ~10s). 
Table 1. Measurements of ∆R2*, FWHM and time-to-peak of the 
concentration time courses for A-MB (0.2 mL of ~4% volume fraction),
SonoVue® (0.2 mL of ~3.5% volume fraction) and MION (0.6 mg 
Fe/kg) in rat brain cortex (mean ± standard deviation, N = 5). 
 ΔR2* (s-1) FWHM (s) Time-to-peak (s) 
A-MB 2.49 ± 1.00 114 ± 39 57 ± 20 
SonoVue® 2.41 ± 1.18 86 ± 16 48 ± 12 
MION 1.98 ± 0.36 N.A. 24 ± 2 
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